Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2

Mohamed S. Bekheit; Siva S. Panda; Adel S. Girgis

doi:10.1016/j.ejmech.2023.115292

Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2

Mohamed S. Bekheit, Siva S. Panda, Adel S. Girgis

Chemistry and Biochemistry

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

The SARS-CoV-2 pandemic is considered as one of the most disastrous pandemics for human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of the key enzymes that control viral replication. RdRp is an attractive and promising therapeutic target for the treatment of SARS-CoV-2 disease. It has attracted much interest of medicinal chemists, especially after the approval of Remdesivir. This study highlights the most promising SARS-CoV-2 RdRp repurposed drugs in addition to natural and synthetic agents. Although many in silico predicted agents have been developed, the lack of in vitro and in vivo experimental data has hindered their application in drug discovery programs.

Original language	English (US)
Article number	115292
Journal	European Journal of Medicinal Chemistry
Volume	252
DOIs	https://doi.org/10.1016/j.ejmech.2023.115292
State	Published - Apr 5 2023

Keywords

COVID-19
Computational studies
Favipiravir
Molnupiravir
Polymerase
RdRp
Remdesivir
SARS-CoV-2

ASJC Scopus subject areas

Pharmacology
Drug Discovery
Organic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejmech.2023.115292

Cite this

@article{23084d39c59649bb8fc0f9c40ccb8ae4,

title = "Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2",

abstract = "The SARS-CoV-2 pandemic is considered as one of the most disastrous pandemics for human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of the key enzymes that control viral replication. RdRp is an attractive and promising therapeutic target for the treatment of SARS-CoV-2 disease. It has attracted much interest of medicinal chemists, especially after the approval of Remdesivir. This study highlights the most promising SARS-CoV-2 RdRp repurposed drugs in addition to natural and synthetic agents. Although many in silico predicted agents have been developed, the lack of in vitro and in vivo experimental data has hindered their application in drug discovery programs.",

keywords = "COVID-19, Computational studies, Favipiravir, Molnupiravir, Polymerase, RdRp, Remdesivir, SARS-CoV-2",

author = "Bekheit, {Mohamed S.} and Panda, {Siva S.} and Girgis, {Adel S.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Masson SAS",

year = "2023",

month = apr,

day = "5",

doi = "10.1016/j.ejmech.2023.115292",

language = "English (US)",

volume = "252",

journal = "European Journal of Medicinal Chemistry",

issn = "0223-5234",

publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2

AU - Bekheit, Mohamed S.

AU - Panda, Siva S.

AU - Girgis, Adel S.

PY - 2023/4/5

Y1 - 2023/4/5

N2 - The SARS-CoV-2 pandemic is considered as one of the most disastrous pandemics for human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of the key enzymes that control viral replication. RdRp is an attractive and promising therapeutic target for the treatment of SARS-CoV-2 disease. It has attracted much interest of medicinal chemists, especially after the approval of Remdesivir. This study highlights the most promising SARS-CoV-2 RdRp repurposed drugs in addition to natural and synthetic agents. Although many in silico predicted agents have been developed, the lack of in vitro and in vivo experimental data has hindered their application in drug discovery programs.

AB - The SARS-CoV-2 pandemic is considered as one of the most disastrous pandemics for human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of the key enzymes that control viral replication. RdRp is an attractive and promising therapeutic target for the treatment of SARS-CoV-2 disease. It has attracted much interest of medicinal chemists, especially after the approval of Remdesivir. This study highlights the most promising SARS-CoV-2 RdRp repurposed drugs in addition to natural and synthetic agents. Although many in silico predicted agents have been developed, the lack of in vitro and in vivo experimental data has hindered their application in drug discovery programs.

KW - COVID-19

KW - Computational studies

KW - Favipiravir

KW - Molnupiravir

KW - Polymerase

KW - RdRp

KW - Remdesivir

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85151420866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151420866&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2023.115292

DO - 10.1016/j.ejmech.2023.115292

M3 - Review article

C2 - 36965227

AN - SCOPUS:85151420866

SN - 0223-5234

VL - 252

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

M1 - 115292

ER -

Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this